Eli Lilly and Company announced on Aug. 3, 2026 that a defined group of patients can now apply for early access to its investigational obesity drug retatrutide, even though the medication has not yet received FDA approval.
Program criteria and launch after physician pressure
The company said it is “actively reviewing requests from health care providers” through a newly acknowledged compassionate‑use pathway. Patients must be at least 18 years old, unable to enroll in a clinical trial, and have refractory obesity with two or more serious complications. One source familiar with the program told a news outlet that applicants also need to have discussed all standard treatment options, while a company spokesperson emphasized that candidates must have failed to lose weight despite tolerating the highest approved dose of an existing obesity therapy. The two descriptions differ slightly, and the discrepancy has not been resolved.
Related: User Blocked After Repeated Violations
The pathway was built after weeks of physician inquiries that followed a single‑patient case earlier this year. In April, Lilly granted a 79‑year‑old patient special compassionate‑use access to retatrutide, an arrangement first reported in June. The application, filed by a senior clinician at the National Institutes of Health, listed refractory obesity, obstructive sleep apnea, and pulmonary hypertension as the patient’s conditions. After the story broke, a White House spokesperson clarified that the patient was not President Donald Trump, who turned 80 in June, and Democratic lawmakers have since asked the administration for more details about the individual’s identity.
Physician experiences and ongoing concerns
Several doctors said they spent weeks waiting for a substantive response from Lilly after submitting compassionate‑use requests. Spencer Nadolsky, DO, and Mike Albert, MD, of the online obesity clinic Vineyard, each applied for multiple patients who had not responded adequately to Lilly’s approved therapy, Zepbound (tirzepatide). Nadolsky reported that one of his patients received only a preliminary qualification, and that clarification came only after a news outlet contacted Lilly for comment.
Angela Fitch, MD, chief medical officer of the obesity clinic knownwell, said clinicians “are owed an explanation of some sort” about whether a formal program exists. Other physicians, including Fatima Cody Stanford, MD, MPH, MPA, of Harvard Medical School and Gitanjali Srivastava, MD, of Vanderbilt University Medical Center, have not yet pursued compassionate use for their patients, citing a desire for more safety data before offering the drug outside a monitored trial setting. Stanford, a clinical investigator on Lilly’s retatrutide trials, suggested the company may not have originally intended to extend access beyond the first patient and now faces a program it perhaps did not plan to build.
Related: Lawmakers Seek to Limit Governor Influence on Abortion Shield Laws
While the new program gives a clearer route for some patients, its reach is likely to stay narrow relative to demand. Qualifying requires both a documented complication burden and, depending on the account, either failure at the maximum approved dose or proof of having discussed standard options. Fitch said she has not yet submitted an application and is still seeking details on whether patients would need to travel to a clinical trial site to receive treatment.
It is possible that the limited scope of the program could prompt other manufacturers to consider similar pathways, especially as the market for obesity therapeutics expands and patients and providers press for faster access to promising agents.
Related: Women Share Stories of Pregnancy Center Experiences
Phase 3 results bolster approval prospects
Retatrutide is a once‑weekly agonist of the gastric inhibitory polypeptide, glucagon‑like peptide‑1, and glucagon receptors. In July, Lilly reported positive initial results from two key phase 3 trials, TRIUMPH‑2 (NCT05929079) and TRIUMPH‑3 (NCT05882045). In TRIUMPH‑2, adults with type 2 diabetes and obesity or overweight lost up to an average of 20.8 % of body weight (about 49.6 lb) at 80 weeks on the highest dose, alongside A1C reductions of up to 1.6 percentage points. In TRIUMPH‑3, adults with severe obesity and established cardiovascular disease lost up to an average of 22.6 % of their body weight (roughly 55.8 lb) at 80 weeks.
Major adverse cardiovascular events occurred numerically less often with retatrutide than with placebo, though the difference did not reach statistical significance. The most common adverse events across both trials were diarrhea, nausea, constipation, and decreased appetite. Lilly said it plans to submit a biologics license application for retatrutide to the FDA in the first quarter of 2027.
